Monosialoganglioside GM3 (bovine)

CAS: 54827-14-4 F: C59H106N2NaO21- W: 1202.46

Monosialoganglioside GM3 (bovine) is a monosialoganglioside and an inhibitor of VEGFR2 and Akt. At a concentration of 20

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Monosialoganglioside GM3 (bovine) is a monosialoganglioside and an inhibitor of VEGFR2 and Akt. At a concentration of 20 μM, Monosialoganglioside GM3 inhibits angiogenesis and reduces the proliferation and migration of human umbilical vein endothelial cells (HUVECs) by inhibiting VEGFR2 and Akt phosphorylation. Ganglioside GM3 also inhibits ferroptosis, providing protective effects during the formation of abdominal aortic aneurysms. Additionally, Monosialoganglioside GM3 (bovine) acts as an inhibitor of insulin signaling, inducing the dissociation of the insulin receptor (IR)-Caveolin-1 complex from lipid microdomains and causing insulin resistance in adipocytes. Monosialoganglioside GM3 (bovine) can be used in cancer and metabolic disease research[1].
CAS	54827-14-4
Formula	C59H106N2NaO21-
Molar Mass	1202.46
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhang F, et al. Ganglioside GM3 Protects Against Abdominal Aortic Aneurysm by Suppressing Ferroptosis. Circulation. 2024 Mar 12;149(11):843-859. [2]. Mukherjee P, et al. Thematic review series: sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a. J Lipid Res. 2008 May;49(5):929-38. [3]. Seyfried TN, et al. Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer. J Oncol. 2010;2010:961243. [4]. Kabayama K, et al. Dissociation of the insulin receptor and caveolin-1 complex by ganglioside GM3 in the state of insulin resistance. Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13678-83.